Bmab-3000

曲妥珠单抗/透明质酸酶 (Biocon Biologics)

Report date: 2026/04/09 20:00:21

Base Information

Drug NameBmab-3000

Drug Alias NameHerceptin HylectaBmab-3000Bmab3000

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsHyaluronic acid modulators

TargetsHyaluronic acidReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsN/A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNew Zealand

CombinationsYes

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesBiocon Biologics UK Plc

China Registration ClassN/A

Develop Information

Active CompaniesBiocon Biologics UK Plc

Inactive CompaniesN/A

Active IndicationsN/A

Inactive IndicationsN/A

Other Information

ATC CodeN/A